Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
MWN-AI** Summary
Bluejay Diagnostics (NASDAQ: BJDX) announced on February 20, 2026, that all prefunded warrants from its October 2025 private placement have been fully exercised, eliminating the outstanding prefunded warrants of any class. As a result, the company now has approximately 972,000 shares of common stock outstanding. Additionally, it holds cash exercisable warrants for around 1.5 million shares, with an exercise price of $7.00 or more per share.
It is noteworthy that recent Schedule 13G filings by investors may be misleading, as they do not account for the 1-for-4 reverse stock split that took place on January 29, 2026. Investors relying on these filings should consider that the reported shareholdings reflect pre-split figures, leading to potentially inflated ownership levels when compared to current shares outstanding.
Bluejay Diagnostics focuses on enhancing patient outcomes through its Symphony System, which enables rapid and cost-effective near-patient testing for sepsis triage and disease monitoring. However, the Symphony System has yet to receive clearance from the U.S. Food and Drug Administration (FDA). The company's flagship product candidate, an IL-6 test aimed at providing quick, accurate results for sepsis, is designed to assist healthcare professionals in making timely treatment decisions.
The company included forward-looking statements in its release, urging caution among investors due to inherent risks and uncertainties. Actual outcomes may differ from those anticipated, and Bluejay acknowledges that these predictions are subject to change. As of the issuance date, the company has no obligation to update any forward-looking statements.
For further information, investors can visit the official Bluejay Diagnostics website or contact Investor Relations.
MWN-AI** Analysis
Bluejay Diagnostics (NASDAQ: BJDX) recently announced that all prefunded warrants from its October 2025 private placement have been fully exercised, resulting in around 972,000 shares of common stock outstanding. This is a crucial milestone for the company, as the absence of remaining prefunded warrants will enhance the overall share structure, thereby potentially appealing to investors seeking stability.
However, investors should exercise caution. The recent reverse stock split (1-for-4) on January 29, 2026, significantly alters the share metrics reported in the Schedule 13G filings. Pre-split, investors may misinterpret beneficial ownership levels, as current holdings are now diluted accordingly. This nuance is critical when evaluating the company's share liquidity and the perceived market capitalization post-split.
Despite the favorable exercise of warrants, Bluejay still faces hurdles, particularly in securing FDA regulatory clearance for its Symphony System, designed for rapid sepsis testing. Regulatory delays can impede growth and investor confidence, as the product’s commercialization remains uncertain. Investors should gauge the timeline to regulatory approval and the company’s cash flow to cover operational needs during this period.
Moreover, the existing cash-exercisable warrants, priced at $7.00 or higher per share, may serve as a potential barrier to share price appreciation in the short term, especially as new investors evaluate entry points.
In summary, while the full exercise of prefunded warrants strengthens Bluejay’s structure, investors must remain vigilant about regulatory risks and market perceptions following the reverse split. A measured entry strategy may be advisable, with a monitored outlook on FDA developments and overall market conditions for medical diagnostics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share.
The Company notes that several recent Schedule 13G filings made by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, and investors reading such filings should be aware that current beneficial ownership share amounts may therefore be significantly less than the number of shares reflected in such reports given that these reports show holdings and total shares outstanding on a pre-split basis, notwithstanding that such reports were filed after consummation of the 1-for-4 reverse stock split.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and in Part II, Item 1A, “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 13, 2025, August 7, 2025 and November 7, 2025, respectively. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com
FAQ**
What strategies does Bluejay Diagnostics Inc. (BJDX) have in place to gain regulatory clearance for the Symphony System, and what timelines do they anticipate for this process?
Given that all prefunded warrants have been exercised, how does Bluejay Diagnostics Inc. (BJDX) plan to utilize the resulting capital to advance its product development and marketing efforts?
With the recent 1-for-4 reverse stock split of Bluejay Diagnostics Inc. (BJDX), what measures are being taken to ensure investors are aware of the accurate current beneficial ownership share amounts?
What specific risk factors does Bluejay Diagnostics Inc. (BJDX) identify that could materially impact its future performance, especially concerning the anticipated rollout of its IL-6 Test for sepsis?
**MWN-AI FAQ is based on asking OpenAI questions about Bluejay Diagnostics Inc. (NASDAQ: BJDX).
NASDAQ: BJDX
BJDX Trading
-3.63% G/L:
$1.86 Last:
28,375 Volume:
$1.90 Open:
